A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
Phase 2
- Conditions
- Alzheimer Disease
- Registration Number
- JPRN-jRCT2031210449
- Lead Sponsor
- Masaki Takeshi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 330
Inclusion Criteria
Gradual and progressive change in memory function reported by participants or informants for >= 6 months
-MMSE score of 22 to 30 (inclusive) at baseline
-CDR global score of 0.5 to 1.0 (inclusive), with a memory box score >=0.5.
-Meet 18F flortaucipir positron emission tomography (PET) scan (central analysis) criteria
-Have a study partner who will provide written informed consent to participate
Exclusion Criteria
-Contraindication to MRI or PET scans
-Have known allergies to LY3372689, related compounds, or any components of the formulations
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change from Baseline to End Time Point in Integrated Alzheimer's Disease Rating Scale (iADRS) [ Time Frame: Baseline, 76 to 124 Weeks ]<br>Change from Baseline to End Time Point in iADRS will be measured in participants with early symptomatic Alzheimer's Disease (AD) with demonstrated presence of moderate levels of tau pathology
- Secondary Outcome Measures
Name Time Method